Discovery Techonologies

Monoclonal Antibody – Interferon (mAb-IFN) Fusion Protein Platform

Caliber has gained access to the mAb-IFN fusion protein platform through its joint venture (Valor Biotherapeutics, www.valorbio.com) with ImmunGene, Inc., (www.immungene.com) mAb-IFN fusion proteins are a new class of therapeutics that are produced by fusing antibodies to tumor cell-killing cytokines (e.g. IFN that are produced by fusing antibodies to tumor cell-killing cytokines)or properties are built into one molecule that is genetically engineered and recombinantly produced. These fusion proteins are thought to kill tumor cells mainly by stimulating apoptosis, in an ADCC (antibody-dependent cell-mediated cytotoxicity)-independent manner (providing the potential to be efficacious in patients with defective ADCC mechanisms), and have the potential to be cytotoxic to tumor cells with low density of targeted surface antigens. They also retain the properties of conventional, non-fused antibody therapeutics in stimulating ADCC and complement-dependent cytotoxicity (CDC) functions. Antibody-cytokine fusion proteins have demonstrated superior efficacy and safety in preclinical studies, validating the therapeutic potential of this technology.

Manufacturing Platforms

Caliber has broad capabilities in plant, cell culture, and microbial-based expression systems. With these capabilities, Caliber maintains the full range of options for biological product development and manufacturing to respond to current unmet patient and global needs.

Caliber is a leader in the Plant-made (N. benthamiana) pharmaceuticals (PMP) production platform. This platform offers a number of advantages over traditional systems for the development and production of protein therapeutics such as monoclonal antibodies.

  • The flexibility and speed of plant technology enables high throughput screening and optimization of biotherapeutics before they ever reach clinical trials.
  • Plants are able to make novel and complex molecular forms that cannot otherwise be produced in cell-based systems, thus providing the opportunity to open new treatment paradigms for patients with unmet medical needs.
  • There are significantly lower facility and production costs associated with plant-based technology.
  • Plant-based systems are more likely to scale to meet increased and varied demand, from personalized to global applications.
  • The speed of production allows accelerated screening of new therapeutics and vaccines against emerging threats including pandemic events.
  • Plant-based technology offers less risk of propagating human pathogens or other mammalian contaminants.